Back

Effect of early initiation of evolocumab on lipid profiles changes in patients with ACS Undergoing PCI (C-STAR)

30 August 2025 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in acute coronary syndromes (3) Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Yongcheol Kim

Yonsei University College of Medicine and Yongin Severance Hospital, Yongin (Korea (Republic of))

6 More presentations in this session

Presentation thumbnail
Comparative effectiveness of prasugrel and ticagrelor among patients undergoing contemporary PCI: insights from the BMC2 registry
Doctor E. Dayoub (Ann Arbor, US)
Abstract Slides Video
Presentation thumbnail
Colchicine for the secondary prevention of cardiovascular diseases: a cumulative-dose meta-analysis of randomized controlled trials including 31,397 subjects worldwide
Assistant Professor Y. Chan (Hong Kong, HK)
Abstract Slides Video
Presentation thumbnail
Early TNF-alpha levels suppression by upstream evolocumab use in patients with acute myocardial infarction undergoing percutaneous coronary intervention
Doctor A. Marengo (Novara, IT)
Abstract Slides Video
Presentation thumbnail
Direct oral anticoagulants vs. vitamin K antagonists for left ventricular thrombus: a paradigm shift in antithrombotic strategy?
Doctor F. Veneziano (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
A very short duration of dual-antiplatelet therapy following percutaneous coronary intervention: a meta-analysis of randomized clinical trials
Doctor J. Sakaleros (Bloomington, US)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy in acute coronary syndromes (3)

The Event

Event poster

ESC Congress 2025

30 August 2025 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Possible shifts in paradigms for lipid-lowering therapies in acute coronary syndrome patients: PCSK9 inhibitors from Day 1
thumbnail
Congress Presentation
Early initiation of PCSK9 inhibitor therapy versus placebo in patients with acute coronary syndrome: a systematic review and meta-analysis
thumbnail
Congress Presentation
Efficacy of combination lipid lowering therapy in achieving low density lipoprotein cholesterol targets after one month of event in patients with acute coronary syndrome

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources